208 related articles for article (PubMed ID: 29861831)
1. Identification of Estrogen Receptor
Pang X; Fu W; Wang J; Kang D; Xu L; Zhao Y; Liu AL; Du GH
Oxid Med Cell Longev; 2018; 2018():6040149. PubMed ID: 29861831
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy.
Yu E; Xu Y; Shi Y; Yu Q; Liu J; Xu L
J Mol Model; 2019 Aug; 25(9):278. PubMed ID: 31463793
[TBL] [Abstract][Full Text] [Related]
3. Discovery of natural estrogen receptor modulators with structure-based virtual screening.
Cao X; Jiang J; Zhang S; Zhu L; Zou J; Diao Y; Xiao W; Shan L; Sun H; Zhang W; Huang J; Li H
Bioorg Med Chem Lett; 2013 Jun; 23(11):3329-33. PubMed ID: 23608764
[TBL] [Abstract][Full Text] [Related]
4. Protein druggability assessment for natural products using in silico simulation: A case study with estrogen receptor and the flavonoid genistein.
Ohbuchi K; Hirokawa T
Gene; 2021 Jul; 791():145726. PubMed ID: 34010704
[TBL] [Abstract][Full Text] [Related]
5. Development of leads targeting ER-α in breast cancer: An in silico exploration from natural domain.
Ashtekar SS; Bhatia NM; Bhatia MS
Steroids; 2018 Mar; 131():14-22. PubMed ID: 29307843
[TBL] [Abstract][Full Text] [Related]
6. Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer.
Luo G; Li X; Zhang G; Wu C; Tang Z; Liu L; You Q; Xiang H
Eur J Med Chem; 2017 Nov; 140():252-273. PubMed ID: 28942113
[TBL] [Abstract][Full Text] [Related]
7. In silico Molecular Modelling of Selected Natural Ligands and their Binding Features with Estrogen Receptor Alpha.
Maruthanila VL; Elancheran R; Roy NK; Bhattacharya A; Kunnumakkara AB; Kabilan S; Kotoky J
Curr Comput Aided Drug Des; 2019; 15(1):89-96. PubMed ID: 30306879
[TBL] [Abstract][Full Text] [Related]
8. Identification of 10-dehydrooxyglycyuralin E as a selective human estrogen receptor alpha partial agonist.
Saito N; Kawase K; Yamashita N; Tang Y; Wang Y; Wang J; Liu Y; Li N; Li W; Cheng MS; Koike K; Kanno Y; Nemoto K
Bioorg Chem; 2019 Jul; 88():102977. PubMed ID: 31100617
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents.
Luo G; Chen M; Lyu W; Zhao R; Xu Q; You Q; Xiang H
Bioorg Med Chem Lett; 2017 Jun; 27(12):2668-2673. PubMed ID: 28460819
[TBL] [Abstract][Full Text] [Related]
10. In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α.
Singh K; Munuganti RS; Leblanc E; Lin YL; Leung E; Lallous N; Butler M; Cherkasov A; Rennie PS
Breast Cancer Res; 2015 Feb; 17(1):27. PubMed ID: 25848700
[TBL] [Abstract][Full Text] [Related]
11. Competitive molecular docking approach for predicting estrogen receptor subtype α agonists and antagonists.
Ng HW; Zhang W; Shu M; Luo H; Ge W; Perkins R; Tong W; Hong H
BMC Bioinformatics; 2014; 15 Suppl 11(Suppl 11):S4. PubMed ID: 25349983
[TBL] [Abstract][Full Text] [Related]
12. Discovery and structure-activity analysis of selective estrogen receptor modulators via similarity-based virtual screening.
Shen J; Jiang J; Kuang G; Tan C; Liu G; Huang J; Tang Y
Eur J Med Chem; 2012 Aug; 54():188-96. PubMed ID: 22647217
[TBL] [Abstract][Full Text] [Related]
13. Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Geiser M; Halleux C; Kallen J; Keller H; Ramage P
J Med Chem; 2005 Jan; 48(2):364-79. PubMed ID: 15658851
[TBL] [Abstract][Full Text] [Related]
14.
Alamri A; Rauf A; Khalil AA; Alghamdi A; Alafnan A; Alshammari A; Alshammari F; Malik JA; Anwar S
Biomed Res Int; 2021; 2021():9734279. PubMed ID: 34957309
[TBL] [Abstract][Full Text] [Related]
15. Selenophenes: Introducing a New Element into the Core of Non-Steroidal Estrogen Receptor Ligands.
Zhang S; Wang Z; Hu Z; Li C; Tang C; Carlson KE; Luo J; Dong C; Katzenellenbogen JA; Huang J; Zhou HB
ChemMedChem; 2017 Feb; 12(3):235-249. PubMed ID: 27976818
[TBL] [Abstract][Full Text] [Related]
16. Prediction of selective estrogen receptor beta agonist using open data and machine learning approach.
Niu AQ; Xie LJ; Wang H; Zhu B; Wang SQ
Drug Des Devel Ther; 2016; 10():2323-31. PubMed ID: 27486309
[TBL] [Abstract][Full Text] [Related]
17. Suppression of breast cancer: modulation of estrogen receptor and downregulation of gene expression using natural products.
Ahmed H; Abdelraheem A; Salem M; Sabry M; Fekry N; Mohamed F; Saber A; Piatti D; Sabry M; Sabry O; Caprioli G
Nat Prod Res; 2024 Jun; 38(11):1997-2006. PubMed ID: 37427947
[TBL] [Abstract][Full Text] [Related]
18. Potential use of an estrogen-glucocorticoid receptor chimera as a drug screen for tissue selective estrogenic activity.
Maru BS; Tobias JH; Rivers C; Caunt CJ; Norman MR; McArdle CA
Bone; 2009 Jan; 44(1):102-12. PubMed ID: 18976723
[TBL] [Abstract][Full Text] [Related]
19. Rational screening of peroxisome proliferator-activated receptor-γ agonists from natural products: potential therapeutics for heart failure.
Chen R; Wan J; Song J; Qian Y; Liu Y; Gu S
Pharm Biol; 2017 Dec; 55(1):503-509. PubMed ID: 27937122
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Novel Selective ERα/ERβ Ligands by Multi-pharmacophore Modeling and Virtual Screening.
Huang W; Wei W; Yang Y; Zhang T; Shen Z
Chem Pharm Bull (Tokyo); 2015; 63(10):780-91. PubMed ID: 26423034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
